Loading
Cancer Genomics and Diagnostics / Breast Cancer Treatment Studies / Breast Lesions and Carcinomas · Journal article
Medical Sciences · August 13, 2026
A consensus or society position rather than new primary data.
This narrative review re-examines the historical and contemporary rationale for current guidelines that place adjuvant chemotherapy before radiotherapy in early breast cancer. While acknowledging the convention rests on asymmetric benefit (locoregional control gains yield half a percentage point mortality benefit via EBCTCG four-to-one relationship, whereas systemic therapy degradation carries undiscounted mortality risk), the authors argue the question remains open and testable in a narrow, contracting population, as retrospective evidence is limited and genomic de-escalation is withdrawing chemotherapy from more favourable phenotypes.
Narrative review. Patients with early breast cancer receiving adjuvant therapy; the population in which the sequencing question remains clinically live is noted as narrow and probably contracting due to genomic de-escalation..
Historical basis relies on a single randomised trial; its distant-metastasis signal did not survive long-term follow-up Contemporary basis: two-point gain in locoregional control yields roughly half a percentage point of mortality benefit once EBCTCG four-to-one relationship is applied One retrospective cohort offers hypothesis-generating locoregional signal qualified by unexpectedly high control-arm event rate and unplanned subgroup analysis
Contemporary basis: two-point gain in locoregional control yields roughly half a percentage point of mortality benefit once EBCTCG four-to-one relationship is applied Another cohort supports only short-term feasibility and tolerability; neither demonstrates benefit in distant control or survival
Clinicians should regard adjuvant chemotherapy-radiotherapy sequencing as an open, testable question rather than settled practice. Current guidelines remain defensible but not immutable; prospective randomized evidence is needed to quantify the absolute loss from chemotherapy delay in the era of hypofractionated radiotherapy.
A narrative review synthesizing historical and contemporary evidence on adjuvant breast cancer treatment sequencing that questions but does not overturn current guidelines, identifying knowledge gaps rather than practice-changing findings.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should regard adjuvant chemotherapy-radiotherapy sequencing as an open, testable question rather than settled practice. Current guidelines remain defensible but not immutable; prospective randomized evidence is needed to quantify the absolute loss from chemotherapy delay in the era of hypofractionated radiotherapy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Guidelines in early breast cancer place adjuvant chemotherapy before radiotherapy, permit radiotherapy concurrently with endocrine and anti-HER2 agents, but discourage it before or during cytotoxic chemotherapy. This narrative review asks whether that convention remains defensible. Its historical basis, a single randomised trial whose distant-metastasis signal did not survive long-term follow-up, is weaker than is commonly assumed. Its contemporary basis is stronger and is stated here explicitly: an asymmetry of absolute benefit, in which a two-point gain in locoregional control yields roughly half a percentage point of mortality benefit once the EBCTCG four-to-one relationship is applied, whereas degradation of systemic therapy reaches mortality undiscounted. We specify three conditions under which a sequencing change could be justified and note that the absolute loss from a short chemotherapy delay cannot presently be quantified from randomised data. Meanwhile, chemotherapy has lengthened while radiotherapy has contracted to a one- to three-week whole-breast schedule, potentially extended when a sequential tumour-bed boost is required. The retrospective evidence is limited: one cohort offers a hypothesis-generating locoregional signal qualified by an unexpectedly high control-arm event rate and an unplanned subgroup analysis, while another supports only short-term feasibility and tolerability; neither demonstrates benefit in distant control or survival. We further argue that the population in which the question remains clinically live is narrow and probably contracting, since genomic de-escalation withdraws from chemotherapy the phenotypes with the most favourable arithmetic. Adjuvant sequencing is best regarded as an open, testable question within a defined population rather than a general case for change.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.